Preliminary observations using HIV-specific transfer factor in AIDS.
Twenty five HIV-1-infected patients, at various stages (CDC II, III and IV) were treated orally with HIV-1-specific transfer factor (TF) for periods varying from 60 to 1870 days. All patients were receiving antiviral treatments in association with TF. The number of lymphocytes, CD4 and CD8 subsets were followed and showed no statistically significant variations. In 11/25 patients the number of lymphocytes increased, whilst in 11/25 decreased; similarly an increase of the CD4 lymphocytes was observed in 11/25 patients and of the CD8 lymphocytes in 15/25. Clinical improvement or a stabilized clinical condition was noticed in 20/25 patients, whilst a deterioration was seen in 5/25. In 12/14 anergic patients, daily TF administration restored delayed type hypersensitivity to recall antigens within 60 days. These preliminary observations suggest that oral HIV-specific TF administration, in association with antiviral drugs, is well tolerated and seems beneficial to AIDS patients, thus warranting further investigation.
Pizza
G
G
Immunodiagnosis and Immunotherapy Unit, Ospedale S. Orsola-Malpighi, Bologna, Italy.
Chiodo
F
F
Colangeli
V
V
Gritti
F
F
Raise
E
E
Fudenberg
H H
HH
De Vinci
C
C
Viza
D
D
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000628:therapy*; D000818:Animals; D019380:Anti-HIV Agents / Q000276:immunology* / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D005260:Female; D006678:HIV / Q000276:immunology*; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D012680:Sensitivity and Specificity; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D014165:Transfer Factor / Q000276:immunology* / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D014165:Transfer Factor